Detailed description page of THPdb

Details of Th1007 which contains 11 entries.

Entry 1
(1) Primary information
ID 1038
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty.
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories Antineoplastic Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Gonadotropin-releasing hormone receptor
Information of corresponding available drug in the market
Brand Name Eligard
Company Atrix Labs/QLT In
Brand Discription ELIGARD is a sterile polymeric matrix formulation of leuprolide acetate, a GnRH agonist, for subcutaneous injection, designed to deliver leuprolide acetate at a controlled rate over a one-, three-, four- or six-month therapeutic period.
Prescribed for Eligard is used to treat the symptoms of prostate cancer in men.
Chemical Name 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate
Formulation ELIGARD is prefilled and supplied in two separate, sterile syringes whose contents are mixed immediately prior to administration. The two syringes are joined and the single dose product is mixed until it is homogenous. One syringe contains the ATRIGEL De
Physcial Appearance Suspension
Route of Administration Subcutaneous Injection
Recommended Dosage 7.5mg-1 injection/month, 22.5mg-1 injection per 3 month, 30mg-1 injection per 4 month, 45 mg- 1 injection every 6 month.
Contraindication Hypersensitivity and pregnancy
Side Effects Rare pain or unusual sensations in your back; numbness, weakness, or tingly feeling in your legs or feet; muscle weakness or loss of use; loss of bowel or bladder control; or liver problems - nausea, upper stomach pain, itching, tired feeling, loss of apetite.
Useful Link Sequence Information Link:http://www.freepatentsonline.com/EP1790656.html# RxMed:http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 2
(2) Primary information
ID 1039
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories Hormonal and Fertility Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Enantone
Company Takeda
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance Solution
Route of Administration Injection
Recommended Dosage One3.75 mg DPS mnthly or one 11.25 mg DPS every 3 month as a single SC/IM injection.
Contraindication Hypersensitivity, undiagnosed abnormal vag bleeding, pregnancy, lactation
Side Effects Weightloss, Parosmia (distortion of the sense of smell, as in smelling odours that are not present), Nausea (feeling of having an urge to vomit), Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves), Mood Swinng.
Useful Link http://www.eligard.com
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 3
(3) Primary information
ID 1040
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories Female and Estrogen Antagonists
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Leuplin
Company Takeda
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration Injection
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.drugs.com/drug-interactions/leuprolide,eligard-index.html
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 4
(4) Primary information
ID 1041
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name LeuProMaxx
Company Baxter/Teva
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.mims.com/THAILAND/drug/info/Enantone%20L-P-
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 5
(5) Primary information
ID 1042
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Leupromer
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration Injection
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link https://www.takeda.com/news/2014/20140905_6740.html
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 6
(6) Primary information
ID 1043
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Lupron
Company Abbott/TAP Pharmaceuticals
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration Injection
Recommended Dosage 7.5 mg for 1-month, 22.5 mg for 3-month, 30 mg for 4-month, and 45 mg for 6-month administration are prescribed for the palliative treatment of advanced prostate cancer, 3.75 mg for 1-month and 11.25 mg for 3-month administration are used for the manageme.
Contraindication Allergic, pregnancy, lactation
Side Effects N.A.
Useful Link http://trademarks.justia.com/761/06/leupromaxx-76106691.html
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 7
(7) Primary information
ID 1044
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Lutrate
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.lupron.com/ http://www.drugs.com/lupron.html
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 8
(8) Primary information
ID 1045
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Memryte
Company Curaxis
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link https://www.takeda.com/news/2012/20120229_3944.html
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 9
(9) Primary information
ID 1046
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Prostap 3
Company Takeda UK Limited
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.rxlist.com/eligard-drug.htm
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 10
(10) Primary information
ID 1047
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Prostap SR
Company Takeda UK Limited
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://clinicaltrials.gov/ct2/show/record/NCT02167893
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

Entry 11
(11) Primary information
ID 1048
ThPP ID Th1007
Therapeutic Peptide/Protein Name Leuprolide
Sequence PHWSYLLR view full sequnce in fasta
Functional Classification IIa
Molecular Weight 1209.3983
Chemical Formula C59H84N16O12
Isoelectric Point N.A.
Hydrophobicity 0.1
Melting Point (℃) N.A.
Half Life Approximately 3 hours
Description Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution 27 L [intravenous bolus administration to healthy male volunteers]
Clearance Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Viadur
Company Bayer AG
Brand Discription N.A.
Prescribed for N.A.
Chemical Name 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-Lleucyl-L-arginyl-N-ethyl-L-prolinamide acetate
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.varianpharmed.com/en/products/gnrh/leupromer
PubMed ID 16370917, 15568711
3-D Structure Th1007 (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1038
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty.
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	Antineoplastic Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Gonadotropin-releasing hormone receptor
Information of corresponding available drug in the market
Brand Name	Eligard
Company	Atrix Labs/QLT In
Brand Discription	ELIGARD is a sterile polymeric matrix formulation of leuprolide acetate, a GnRH agonist, for subcutaneous injection, designed to deliver leuprolide acetate at a controlled rate over a one-, three-, four- or six-month therapeutic period.
Prescribed for	Eligard is used to treat the symptoms of prostate cancer in men.
Chemical Name	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate
Formulation	ELIGARD is prefilled and supplied in two separate, sterile syringes whose contents are mixed immediately prior to administration. The two syringes are joined and the single dose product is mixed until it is homogenous. One syringe contains the ATRIGEL De
Physcial Appearance	Suspension
Route of Administration	Subcutaneous Injection
Recommended Dosage	7.5mg-1 injection/month, 22.5mg-1 injection per 3 month, 30mg-1 injection per 4 month, 45 mg- 1 injection every 6 month.
Contraindication	Hypersensitivity and pregnancy
Side Effects	Rare pain or unusual sensations in your back; numbness, weakness, or tingly feeling in your legs or feet; muscle weakness or loss of use; loss of bowel or bladder control; or liver problems - nausea, upper stomach pain, itching, tired feeling, loss of apetite.
Useful Link	Sequence Information Link:http://www.freepatentsonline.com/EP1790656.html# RxMed:http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(2) Primary information
Entry 2
ID	1039
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	Hormonal and Fertility Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Enantone
Company	Takeda
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	Solution
Route of Administration	Injection
Recommended Dosage	One3.75 mg DPS mnthly or one 11.25 mg DPS every 3 month as a single SC/IM injection.
Contraindication	Hypersensitivity, undiagnosed abnormal vag bleeding, pregnancy, lactation
Side Effects	Weightloss, Parosmia (distortion of the sense of smell, as in smelling odours that are not present), Nausea (feeling of having an urge to vomit), Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves), Mood Swinng.
Useful Link	http://www.eligard.com
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(3) Primary information
Entry 3
ID	1040
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	Female and Estrogen Antagonists
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Leuplin
Company	Takeda
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	Injection
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.drugs.com/drug-interactions/leuprolide,eligard-index.html
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(4) Primary information
Entry 4
ID	1041
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	LeuProMaxx
Company	Baxter/Teva
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.mims.com/THAILAND/drug/info/Enantone%20L-P-
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(5) Primary information
Entry 5
ID	1042
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Leupromer
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	Injection
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	https://www.takeda.com/news/2014/20140905_6740.html
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(6) Primary information
Entry 6
ID	1043
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Lupron
Company	Abbott/TAP Pharmaceuticals
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	Injection
Recommended Dosage	7.5 mg for 1-month, 22.5 mg for 3-month, 30 mg for 4-month, and 45 mg for 6-month administration are prescribed for the palliative treatment of advanced prostate cancer, 3.75 mg for 1-month and 11.25 mg for 3-month administration are used for the manageme.
Contraindication	Allergic, pregnancy, lactation
Side Effects	N.A.
Useful Link	http://trademarks.justia.com/761/06/leupromaxx-76106691.html
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(7) Primary information
Entry 7
ID	1044
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Lutrate
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.lupron.com/ http://www.drugs.com/lupron.html
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(8) Primary information
Entry 8
ID	1045
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Memryte
Company	Curaxis
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	https://www.takeda.com/news/2012/20120229_3944.html
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(9) Primary information
Entry 9
ID	1046
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Prostap 3
Company	Takeda UK Limited
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.rxlist.com/eligard-drug.htm
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(10) Primary information
Entry 10
ID	1047
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Prostap SR
Company	Takeda UK Limited
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://clinicaltrials.gov/ct2/show/record/NCT02167893
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)

(11) Primary information
Entry 11
ID	1048
ThPP ID	Th1007
Therapeutic Peptide/Protein Name	Leuprolide
Sequence	PHWSYLLR view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	1209.3983
Chemical Formula	C59H84N16O12
Isoelectric Point	N.A.
Hydrophobicity	0.1
Melting Point (℃)	N.A.
Half Life	Approximately 3 hours
Description	Leuprolide is a synthetic 9 residue peptide analog of gonadotropin releasing hormone belonging to the class of drugs called hormones or hormone antagonists. It is used to treat advanced prostate cancer, uterine fibroids and endometriosis (under investigation for possible use in the treatment of mild to moderate Alzheimer's disease).
Indication/Disease	To treat prostate cancer, endometriosis, uterine fibroids and premature puberty
Pharmacodynamics	Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis thus used in the palliative treatment of advanced prostate cancer.
Mechanism of Action	Leuprolide binds to the gonadotropin releasing hormone receptor and acts as an efficient inhibitor of gonadotropin secretion.
Toxicity	Subcutaneous administration of 250 to 500 times the recommended human dose in rats, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a
Metabolism	Primarily degraded by peptidase (instead of cytochrome P450 enzymes).
Absorption	Bioavailability by subcutaneous administration is comparable to that by intravenous administration.
Volume of Distribution	27 L [intravenous bolus administration to healthy male volunteers]
Clearance	Excretion in urine, 8.34 L/hour [healthy male receiving a 1-mg IV bolus]
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Viadur
Company	Bayer AG
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-Lleucyl-L-arginyl-N-ethyl-L-prolinamide acetate
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.varianpharmed.com/en/products/gnrh/leupromer
PubMed ID	16370917, 15568711
3-D Structure	Th1007 (View) or (Download)